Dublin, July 14, 2025 (GLOBE NEWSWIRE) — The “Tumor Profiling Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” has been added to ResearchAndMarkets.com’s offering.
The Global Tumor Profiling Market is expected to reach US$ 26.56 billion by 2033 from US$ 11.34 billion in 2024, with a CAGR of 9.92% from 2025 to 2033.
The use of precision oncology, which customizes treatments according to a tumor’s particular genetic composition, and the increase in cancer incidence are the main drivers of market expansion. Technological developments like next-generation sequencing are making tumor profiling faster and more accurate, which is promoting its broad use in cancer.
Growth Drivers for the Tumor Profiling Market Developments in Precision Medicine and Genomics
The research of cancer and its treatment methods have been completely transformed by developments in genomic technology, such as NGS and proteomics. This is the reason for the rapid expansion of the tumor profiling market. Such cutting-edge technologies enable thorough tumor profiling, which in turn enables the development of customized treatments based on each patient’s unique genetic composition. Treatment outcomes are getting better, and giving cancer patients precise care is becoming more important.
According to reports, global spending in cancer treatment reached roughly USD 196 billion in 2022, growing at an average annual pace of about 12% during the previous five years. Advanced genomic technologies are increasingly being used for tumor profiling as a result of the rising need for novel diagnostic and therapeutic applications. By altering the oncology landscape and paving the path for more efficient and focused cancer therapies, these advancements are improving the prognosis for the cancer/tumor profiling industry.
Funding from the Government and Research
Tumor profiling is being boosted by the significant increase in funding and investment in precision medicine and cancer. Governments, pharmaceutical firms, and other research groups work together to develop more sophisticated profiling solutions that accelerate the development of cancer therapy and early diagnostic techniques.
According to Cancer Research UK, the UK government has pledged to raise its overall spending in research and development (R&D) to 2.4% of GDP by 2027. The need for cancer/tumor profiling is driven by several projects, which highlight the increased emphasis on innovation in cancer diagnosis and therapies. In addition to increasing access to precision medicine, these investments support ground-breaking advancements in cancer therapy that are tailored to each patient’s needs, which in turn drives market expansion.
Growing Cancer Prevalence
This rise has been significantly accelerated by the rising incidence of cancer worldwide. The prevalence of cancer is at its highest point, and as the need for precise and targeted diagnosis solutions to improve patient outcomes grows yearly, so does the need for sophisticated tumor profiling techniques. According to the American Cancer Society, 9.7 million people died from cancer in 2022, with roughly 20 million new cases diagnosed globally. This alarming pattern emphasizes how urgently improved diagnostic and therapeutic alternatives are needed.
Furthermore, it is predicted that by 2050, there may be 35 million instances of cancer due to a combination of environmental influences, lifestyle changes, and an aging population. These figures demonstrate how tumor profiling is becoming more and more important in meeting the need for individualized treatments and increased cancer patient survival.
Challenges in the Tumor Profiling Market High Cost of Profiling Technologies
There is substantial cost ramifications associated with the new technologies utilized in tumor profiling, including as transcriptomics, proteomics, and next-generation sequencing (NGS). These techniques need for state-of-the-art technology, which is costly to purchase and maintain. The consumables and reagents required for these tests also add to the overall high cost. The results must be analyzed by qualified staff, such as molecular biologists and bioinformaticians, which drives up expenses even further. Because healthcare funds are tight in low- and middle-income nations, this cost barrier is especially significant there. As a result, many patients could not have access to these crucial diagnostic resources, which would restrict tumor profiling’s worldwide reach and efficacy in addressing inequities in cancer care.
Data Interpretation Complexity
Interpreting the enormous volumes of intricate genomic and molecular data generated by tumor profiling is a difficult undertaking. Both in-depth understanding of the cancer genome and specific bioinformatics skills are needed for the study. Because mutations might vary from one area of the tumor to another, tumor heterogeneity – the changes within a single tumor’s cells – makes it even more difficult to interpret data.
Furthermore, cancer mutations are constantly changing, which makes it difficult to provide reliable, useful insights. The issue is made worse by our incomplete knowledge of some genetic variations, especially in uncommon or poorly researched malignancies. Tumor profiling is more difficult to use clinically if accurate data interpretation is not available to provide individualized therapy choices.
Key Players Analyzed:
- Illumina Inc.
- Qiagen N.V.
- Exact Sciences Corporation
- NeoGenomics Laboratories
- Oxford Gene Technology IP Limited
- Bruker Spatial Biology, Inc.
- GenomeDX
- Guardant Health
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024 – 2033 |
| Estimated Market Value (USD) in 2024 | $11.34 Billion |
| Forecasted Market Value (USD) by 2033 | $26.56 Billion |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Tumor Profiling Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Tumor Profiling Market Share Analysis
6.1 By Technique
6.2 By Technology
6.3 By Application
6.4 By Countries
7. Technique
7.1 Genomics
7.2 Proteomics
7.3 Metabolomics
7.4 Epigenetics
8. Technology
8.1 Immunoassays
8.2 Next-Generation Sequencing
8.3 Polymerase Chain Reaction
8.4 In Situ Hybridization
8.5 Microassays
8.6 Mass Spectrometry
8.7 Others
9. Application
9.1 Personalized Cancer Medicine
9.2 Oncological Diagnostics
9.3 Research
10. Countries
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia-Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa
11. Porter’s Five Forces Analysis
12. SWOT Analysis
13. Key Players Analysis
- Illumina Inc.
- Qiagen
- Exact Sciences Corporation
- NeoGenomics Laboratories
- Oxford Gene Technology IP Limited
- Bruker Spatial Biology, Inc.
- GenomeDX
- Guardant Health
For more information about this report visit https://www.researchandmarkets.com/r/8gf6s
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
